Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

555 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sutimlimab in Cold Agglutinin Disease.
Röth A, Barcellini W, D'Sa S, Miyakawa Y, Broome CM, Michel M, Kuter DJ, Jilma B, Tvedt THA, Fruebis J, Jiang X, Lin S, Reuter C, Morales-Arias J, Hobbs W, Berentsen S. Röth A, et al. Among authors: miyakawa y. N Engl J Med. 2021 Apr 8;384(14):1323-1334. doi: 10.1056/NEJMoa2027760. N Engl J Med. 2021. PMID: 33826820 Clinical Trial.
Complement C1s inhibition with sutimlimab results in durable response in cold agglutinin disease: CARDINAL study 1-year interim follow-up results.
Roth A, Barcellini W, D'Sa S, Miyakawa Y, Broome CM, Michel M, Kuter DJ, Jilma B, Tvedt THA, Weitz IC, Patel P, Jiang X, Reuter C, Su J, Shafer F, Lee M, Berentsen S. Roth A, et al. Among authors: miyakawa y. Haematologica. 2022 Jul 1;107(7):1698-1702. doi: 10.3324/haematol.2021.279812. Haematologica. 2022. PMID: 35172561 Free PMC article. No abstract available.
The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.
Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon SS, Kavanagh D, Haller H; 311 Study Group. Rondeau E, et al. Among authors: miyakawa y. Kidney Int. 2020 Jun;97(6):1287-1296. doi: 10.1016/j.kint.2020.01.035. Epub 2020 Mar 6. Kidney Int. 2020. PMID: 32299680 Free article. Clinical Trial.
[TTP and aHUS: new insights].
Miyakawa Y. Miyakawa Y. Rinsho Ketsueki. 2017;58(5):530-536. doi: 10.11406/rinketsu.58.530. Rinsho Ketsueki. 2017. PMID: 28592771 Japanese.
Safety and effectiveness of eculizumab for adult patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
Kato H, Miyakawa Y, Hidaka Y, Inoue N, Ito S, Kagami S, Kaname S, Matsumoto M, Mizuno M, Matsuda T, Shimono A, Maruyama S, Fujimura Y, Nangaku M, Okada H. Kato H, et al. Among authors: miyakawa y. Clin Exp Nephrol. 2019 Jan;23(1):65-75. doi: 10.1007/s10157-018-1609-8. Epub 2018 Jun 29. Clin Exp Nephrol. 2019. PMID: 29959568 Free PMC article.
555 results